“…In general, bench-tobedside translation of nanoparticles and dendrimers in particular, remains an important challenge. Indeed, to date, few dendrimers are in the clinical phase for systemic administration (vide supra), despite the fact that dendrimers are the focus of a large number of research publications, with approximately 2500 between 2006 and 2013 [90,91]. In addition, specifically regarding the use of dendrimers as MRI agents, McMahon and Bulte [14] have highlighted that over the last two decades, there has been an explosion of studies in MRI theranostics with over 400 papers published and 2800 citations a year (2013-2016).…”